Medicinal and Recreational Marijuana Use by Patients Infected with HIV

AIDS Patient Care and STDs

Volumn 18, Issue 4, 2004, Pages 215-228

  Furler, Michelle D ^a   Einarson, Thomas R ^a,b   Millson, Margaret ^a   Walmsley, Sharon ^c   Bendayan, Reina ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APPETITE STIMULANT; CANNABIS; DRONABINOL; NABILONE;

ADULT; APPETITE DISORDER; CANADA; CANNABIS ADDICTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PAIN; POVERTY; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; SELF REPORT; SEX DIFFERENCE; SEX RATIO; WEIGHT GAIN;

ADULT; APPETITE STIMULANTS; CANNABIS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MARIJUANA SMOKING; ONTARIO; PAIN; PHYTOTHERAPY; PLANT PREPARATIONS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 2342444013     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104323038892     Document Type: Review

References (44)

1. Nolin PC, Kenny C, Banks T, et al. Cannabis: Our position for a Canadian public policy. Report of the Senate Special Committee on Illegal Drugs, Volumes I-III. Ottawa, Ontario: Senate Special Committee on Illegal Drugs; 2002. [in three parts]. www.parl. gc.ca/37/1/parlbus/commbus/senate/com-e/illee/rep-e/repfinalvol1-e.pdf; www.parl.gc.ca/37/1/parlbus/commbus/senate/com-e/ille-e/rep-e/repfinalvol2-e. pdf; www.parl.gc.ca/37/1/parlbus/commbus/senate/com-e/ille-e/rep-e/rep finalvol3-e.pdf (Last accessed October 17, 2000).
2. British Columbia Compassion Club Society. Operational Standards for the Distribution of Medicinal Cannabis. 2003. thecompassionclub.org/club/standardsapr30.pdf (Last accessed December 11, 2003).
3. Senate and House of Commons of Canada. Controlled Drugs and Substances Act, Part VI 1996, c. 19, s.56.
4. Erickson B. Controlled Drugs and Substances Act-Marihuana Medical Access Regulations. Registration SOR 2001-277 (JUS-602460), Ottawa, Ontario: Policy and Regulatory Affairs Division. June 2001.3.
5. Ogborne A, Smart R. Cannabis users in the general Canadian population. Subst Use Misuse 2000;35: 301-311.
6. Canadian Centre on Substance Abuse. Canadian profile 1999: Illicit drugs: Highlights, 1999. Retrieved: November 26, 2002, from http://www.ccsa.ca/Profile/cp99ill.htm
7. Ogborne A, Smart R, Adlaf E. Self-reported medicinal use of marijuana: A survey of the general population. CMAJ 2000;162:1685-1686.
8. Research Group on Drug Use. Drug use in Toronto-2000. www.toronto.ca/drugoentre/rgdu00/rgdul.htm (Last accessed November 26, 2002).
9. Office of Applied Studies. Results from the 2001 National Household Survey on drug abuse: Volume II. Technical appendices and selected data tables. NHSDA Series H-18. DHHS Pub. No. (SMA) 02-3759. Rockville, MD: Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services, 2002.
10. Wesner B. The medicinal marijuana issue among PWAS: Reports of therapeutic use and attitudes towards legal reform. Working Paper No. 3., Working Paper Series. Drug Research Unit, Social Science Institute, University of Hawaii, Manoa: 1996. www. lindesmith.org/library/mmjwesne.cfm (Last accessed November 14, 2002).
11. Dansak DA. Medical use of recreational drugs by AIDS patients. J Addict Dis 1997;16:25-30.
12. Ware M, Rueda S, Singer J, Kilby D. Cannabis use by persons living with HIV/AIDS: Patterns and prevalence of use. J Cannabis Therapeutics 2003;3:3-15.
13. Joy J, Watson S, Benson J (eds.) Marijuana and Medicine Assessing the Science Base. [Electronic Version] Washington, DC: National Academy Press; 1999. books.nap.edu/html/marimed/notice.html (Last accessed October 1, 2002).
14. NSW (New South Wales) Working Party on the Use of Cannabis for Medicinal Purposes. Report of the Working Party on the Use of Cannabis for Medical Purposes, Volumes I-II. Sydney, Australia: Parliament House, 2000.
15. Guzman M. Cannabinoids: Potential anticancer agents. Nat Rev Cancer 2003;3:745-755.
16. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001;178:107-115.
17. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Can J Neurol Sci, 30:201-205, 2003.
18. Braitstein P, Kendall T, Chan K, et al. Mary-Jane and her patients: Sociodemographic and clinical characteristics of HIV-positive individuals using medicinal marijuana and antiretroviral agents. AIDS 2001;15: 532-533.
19. Fairfield KM, Eisenberg DM, Davis RB et al. Patterns of use, expenditures, perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med 1998;158:2257-2264.
20. Chen K, Kandel DB. Predictors of cessation of marijuana use: An event history analysis. Drug Alcohol Depend 1998;50:109-121.
21. Millson ME, Rachlis A, Robinson GA, Peter A. HIV Ontario Observational Database: A foundation for growth in HIV/AIDS research. Ontario Med Rev 1995;62:22-24.
22. Millson P, Leeb K, Cameron B, Major C, Palmer R, HOOD. Assessing representativeness in the HIV Ontario observational database-What is population-based research anyway? (Abstract Tu.C.48050). International Conference on AIDS 1996;11:377.
23. Forte T, Bayoumi AM, Remis RS et al. Representativeness of the HIV Ontario Observational Database (HOOD) [Poster]. Canadian Association For HIV Research (CAHR) 2003: Halifax, Nova Scotia, Canada.
24. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Use of complementary and alternative medicine by HIV infected outpatients in Ontario, Canada. AIDS Patient Care STDs 2003;17:155-168.
25. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003;362: 1517-1526.
26. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-135.
27. Pertwee RG. Cannabinoids and pain. Prog Neurobiol 2001;63:569-611.
28. Rice ASC. Cannabinoids and pain. Curr Opin Invest Drugs 2001;2:399-414.
29. Ogborne A, Smart R, Weber T, Birchmore-Timney C. Who is using cannabis as medicine and why: An exploratory study. J Psychoactive Drugs 2000;32: 435-443.
30. Craib KJ, Weber AC, Cornelisse PG, et al. Comparison of sexual behaviors, unprotected sex, and substance use between two independent cohorts of gay and bisexual men. AIDS 2000;14:303-311.
31. Tindall B, Cooper DA, Donovan B, et al. The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust NZ J Med 1988;18:8-15.
32. Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-662.
33. Caiaffa WT, Vlahov D, Graham NM, et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 1994;150: 1493-1498.
34. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003;79:59-61.
35. Srivastava MD, Srivastava BI, Brouhard B. Delta-9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998;40:179-185.
36. Klein TW, Newton C, Larson K, et al. The cannabinoid system and immune modulation. J Leukocyte Biol 2003;74:486-496.
37. Whitfield RM, Bechtel LM, Starich GH. The impact of ethanol and marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcohol Clin Exp Res 1997;21:122-127.
38. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 2002;42 (suppl):82S-89S.
39. Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann Intern Med 2003;139:258-266.
40. Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002;16:543-550.
41. Block RI. Does heavy marijuana use impair human cognition and brain function [Letter] JAMA 1996; 275:560-561.
42. Hall W, MacPhee D. Cannabis use and cancer [Editorial]. Addiction 2002;97:243-247.
43. Khalsa JH, Genser S, Francis H, Martin B. Clinical consequences of marijuana. J Clin Pharmacol 2002;42 (suppl):7S-10S.
44. Tashkin DR, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 2002;42(suppl): 71S-81S.